Institutional investors purchased a net $4.6 million shares of HALO during the quarter ended September 2016. This may signal that the smart money is gaining interest in this company as the 71.76% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
IRIDIAN ASSET MANAGEMENT LLC Bought 1.4 Million shares of Halozyme Therapeutics Inc
BLACKROCK ADVISORS LLC Bought 1.1 Million shares of Halozyme Therapeutics Inc